Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Schwannomatosis 1Pain 1Neurilemmoma 1Neoplasm Metastasis 1Multiple Myeloma 1Hereditary Sensory and Autonomic Neuropathies 1Cancer Pain 1

Interventions

Morphine 16Oxycodone 14Fentanyl 10Methadone 7nabiximols 5Lidocaine 5Acetaminophen 5resiniferatoxin 4Hydromorphone 4Ethanol 4Acupuncture Therapy 4Transcutaneous Electric Nerve Stimulation 3Buprenorphine 3Transcranial Direct Current Stimulation 2Tapentadol 2Surveys and Questionnaires 2Standard of Care 2Sodium Bicarbonate 2Radiosurgery 2Radiofrequency Ablation 2Pharmaceutical Services 2Naloxone 2Ketamine 2Electroacupuncture 2Dronabinol 2Control Groups 2Analgesics, Opioid 26'-fluoro-4',9'-dihydro-N,N-dimethyl-4-phenylspiro(cyclohexane-1,1'(3'H)-pyrano(3,4-b)indol)-4-amine 2tanezumab 1rofecoxib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Cancer Pain × tanezumab × Clear all
NCT02609828 2023-02-16

Phase 3 Study on the Efficacy and Safety of Tanezumab in Patients With Cancer Pain Due to Bone Metastasis Who Are Taking Background Opioid Therapy

Pfizer

Phase 3 Completed
156 enrolled 31 charts
Plasma cell

Cancer Pain, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡